World News Insights
1-3 Minute Gist

Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.

All Topics Articles

LyrArc brings in selected articles from many of the world's top publications.

Articles are selected by experts and you can see the gist of the important articles.

Teva Pharmaceutical to Cut 14,000 Jobs

  
WSJ - 12.14.2017 Original article ›
Rory Jones In Tel Aviv, Austen Hufford In New York
LyrArc Article Gist
A faltering generics business leads Teva Pharmaceutical to layoff 25% of its employees. Falling prices of generics and a MS drug are hurting Teva's business. A major acquisition had already caused the company to load up on debt. Management is divided on what strategy to adopt.

Read LyrArc gist ›
Original article 3 minutes, gist 1 minute

Teva Pharmaceuticals Hit by Increased Competition in U.S. Generics

6 Groups   
WSJ - 08.03.2017 Original article ›
Denise Roland In London, Rory Jones In Tel Aviv

Teva Pharmaceuticals to Buy Allergan’s Generics Business

2 Groups   
New York Times - 07.27.2015 Original article ›
Michael J. De La Merced, Michael, J., De, La, Merced, Chad Bray, Chad, Bray

Teva to Acquire Top German Generics Maker for $5 Billion

2 Groups   
New York Times - 03.18.2010 Original article ›
Natasha Singer, Natasha, Singer
LyrArc Article Gist
Teva has agreed to acquire German generic pharmaceutical maker Ratiopharm for 3.62 billion euros. Germany is the second largest generics market in the world at $8.8 billion and the acquisition makes Teva the top generics company in Europe.
Read LyrArc gist ›

Teva Will Stop Making Anesthetic

3 Groups   
Wall Street Journal - 05.28.2010 Original article ›
Alicia Mundy, Alicia, Mundy
LyrArc Article Gist
After recalls of some Propofol anesthetic product in July 2009, Teva Pharmaceutical has decided to stop making the anesthetic. The FDA had found significant manufacturing violations at Teva's Irvine plant.
Read LyrArc gist ›

Teva Poised to Get a Big Boost in Generics

10 Groups   
Wall Street Journal - 07.27.2015 Original article ›
Jonathan Rockoff, Jonathan, Rockoff, Dana Mattioli, Dana, Mattioli, And Liz Hoffman, And, Liz, Hoffman
LyrArc Article Gist
Teva Pharmaceutical plans to acquire the generic drug business of Allergan in 2015. Teva's sales of generics were $9.1 billion in 2014, according to EvaluatePharma, over 50% of its total sales, and 12% of global market. Alergan had $6.6 billion in generic sales in 2014. Allergan's strategy is to move up the market to branded drugs because of price competition from India in generic drugs. Teva's strategy is to increase the size of its generic business to better tackle pricing issues.
Read LyrArc gist ›

Generic-Drug Firms Get Bolder

4 Groups   
Wall Street Journal - 02.06.2008 Original article ›
Thomas Gryta, Thomas, Gryta
LyrArc Article Gist
Teva's at-risk-launches of generic versions including Wyeth's Protonix and taking about 60% of the prescriptions written for Protonix. Its a profitable strategy for Teva Pharmacetical.
Read LyrArc gist ›

Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges

  
WSJ - 08.21.2023 Original article ›
Dave Michaels
LyrArc Article Gist
The US Justice Department imposes a $225 million fine on Teva Pharmaceutical and requires it to sell its Pravastatin drug line as part of a deferred prosecution settlement on price fixing charges. The  public was overcharged by $350 million according to a 2020 indictment. Collective fines on price fixing charges in the generic rugs industry amount to $680 million reports WSJ. Teva will also have to donate $50 million to needy patients. This is another way the Biden Justice Department is bringing down the cost of living by keeping a close eye on drug costs pushed up by illegal price fixing. 

Read LyrArc gist ›

Mylan’s Leverage to Resist Teva Deal Reveals Shift in Rules

1 Groups   
Wall Street Journal - 07.28.2015 Original article ›
Shayndi Raice And Liz Hoffman, Shayndi, Raice, And, Liz, Hoffman
LyrArc Article Gist
Mylan's shift of headquarters to the Netherlands has helped fend off takeover moves by Teva Pharmaceutical, because of the greater protection offered by laws in the Netherlands.
Read LyrArc gist ›

Wyeth Hit by Generic Competition and Regulatory Setback

3 Groups   
New York Times - 12.25.2007 Original article ›
Bloomberg News, Bloomberg, News
LyrArc Article Gist
Generics from Teva Pharmaceuticals hurt Wyeth as Teva starts a generic for Protonix a heartburn medicine.
Read LyrArc gist ›

Teva Deal Probe Gets Extension

2 Groups   
Wall Street Journal - 12.03.2008 Original article ›
Wsj Print, Wsj, Print
LyrArc Article Gist
Teva Pharmaceutical's acquisition of generic drug maker Barr Pharmaceutical for $7.46 billion to strengthen its position in emerging markets and expand its product portfolio.
Read LyrArc gist ›

Wyeth Loses Bout in Fight on a Generic

3 Groups   
New York Times - 09.08.2007 Original article ›
Stephanie Saul, Stephanie, Saul
LyrArc Article Gist
Protonix or Pantoprazole Wyeth's third best selling drug with sales of $1.8 billion has patent that expires in July 2010. Now a judge has ruled that Teva Pharmaceutical can introduce its generic version of this drug, Teva had filed a suit challenging the patent's validity and the judge ruled rejecting Wyeth's request to block the generic version from being marketed. Pantoprazole is used to treat severe inflammation of the esophagus from excess acid production.
Read LyrArc gist ›

Generic-Drug Firms Go Beyond Knockoffs

11 Groups   
Wall Street Journal - 06.15.2013 Original article ›
Jonathan D. Rockoff, Jonathan, D., Rockoff

Teva Names a New Chief Executive

7 Groups   
New York Times - 01.02.2012 Original article ›
Bloomberg News, Bloomberg, News

Teva Is Easy Pill to Swallow

1 Links 7 Groups   
Wall Street Journal - 05.08.2012 Original article ›
Spencer Jakab, Spencer, Jakab

Former Test-Tube Washer Built Generic-Drug Maker Teva

1 Links 3 Groups   
Wall Street Journal - 11.23.2011 Original article ›
Stephen Miller, Stephen, Miller

Split at Teva as CEO Exits

4 Groups   
Wall Street Journal - 10.31.2013 Original article ›
Rockoff, Loftus

Generic Drug Makers Facing Squeeze on Revenue

6 Groups   
New York Times - 12.03.2012 Original article ›
Katie Thomas, Katie, Thomas
LyrArc Article Gist
In 2012 40 brand name drugs with sales value of $35 billion lost patent protection. In 2013 this figure falls to $17 billion, according to analysts at Credit Agricole Securities. This means the opportunities for generics makers is diminishing. This is leading to consolidation and specialization by generics makers.
Read LyrArc gist ›

Teva Profit Rises 7%

4 Groups   
Wall Street Journal - 05.12.2011 Original article ›
Thomas Gryta, Thomas, Gryta

Mylan Rejects Teva’s $40 Billion Takeover Offer

11 Groups   
New York Times - 04.27.2015 Original article ›
Michael J. De La Merced, Michael, J., De, La, Merced

Threat of Generic Copycat Comes Back to Nip at Teva

3 Groups   
Wall Street Journal - 07.25.2011 Original article ›
Jonathan D. Rockoff, Jonathan, D., Rockoff

AstraZeneca, Teva Set Accord on Asthma Drug

2 Groups   
Wall Street Journal - 11.25.2008 Original article ›
Sarah Rubenstein, Sarah, Rubenstein

Teva to Shed 5,000 Employees

3 Groups   
Wall Street Journal - 10.11.2013 Original article ›
Peter Loftus, Peter, Loftus

After Long Pursuit, Teva Wins Cephalon

2 Groups   
Wall Street Journal - 05.03.2011 Original article ›
Jonathan D. Rockoff, Jonathan, D., Rockoff

Teva Generic Approved; Court Blocks Launch

1 Groups   
Wall Street Journal - 05.21.2007 Original article ›
Wsj Print, Wsj, Print

Support LyrArc

We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.

Support Lyrarc from as small as $1




Support LyrArc →


Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us